5th TCR-based Therapies for Solid Tumors Summit 2024
Evvnt Promotion / evvnt
Archivio
23.04.2024 - 25.04.2024 Hilton Boston Back Bay, 40 Dalton Street, 02115 Boston, Massachusetts, USA
Time: 9:00 AM - 5:30 PM
Temi della conferenza
Our core commitment centers on advancing R and D and Clinical Development strategies for TCR therapies, aiming to harness their immense potential in targeting solid tumors. These therapies offer promising avenues for enhancing treatment methodologies, thereby fostering optimism for improved outcomes among patients grappling with these challenging conditions.
Our core commitment centers on advancing R and D and Clinical Development strategies for TCR therapies, aiming to harness their immense potential in targeting solid tumors. These therapies offer promising avenues for enhancing treatment methodologies, thereby fostering optimism for improved outcomes among patients grappling with these challenging conditions.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
Brochure: https://go.evvnt.com/2147535-3?pid=4832
Speakers: Alfred Lim, Head of Pipeline Research, Etcembly, Andrew Bayliffe, Chief Scientific Officer, Marengo Therapeutics, Cagan Gurer, Vice President Disovery, TScan Therapeutics, and more
Brochure: https://go.evvnt.com/2147535-3?pid=4832
Speakers: Alfred Lim, Head of Pipeline Research, Etcembly, Andrew Bayliffe, Chief Scientific Officer, Marengo Therapeutics, Cagan Gurer, Vice President Disovery, TScan Therapeutics, and more
Informazioni ed Iscrizioni:
https://go.evvnt.com/2147535-2?pid=4832
Ms. Kate Woodford
Medicina General
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
